Cargando…
Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis
Bisoprolol is a drug that acts via the mechanism of specifically and selectively inhibiting the β(1)-adrenoreceptor in cardiac myocytes, and provides a pure reduction of heart rate without changing other cardiac parameters. It has long been clinically used to treat cerebrovascular and cardiovascular...
Autores principales: | Xiang, Shizhao, Zhang, Ning, Yang, Zheng, Bian, Zhouyan, Yuan, Yuan, Tang, Qizhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038470/ https://www.ncbi.nlm.nih.gov/pubmed/27698689 http://dx.doi.org/10.3892/etm.2016.3570 |
Ejemplares similares
-
Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017) -
Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis
por: Bian, Zhouyan, et al.
Publicado: (2009) -
Never in Mitosis Gene A Related Kinase-6 Attenuates Pressure Overload-Induced Activation of the Protein Kinase B Pathway and Cardiac Hypertrophy
por: Bian, Zhouyan, et al.
Publicado: (2014) -
OSMR deficiency aggravates pressure overload-induced cardiac hypertrophy by modulating macrophages and OSM/LIFR/STAT3 signalling
por: Feng, Yizhou, et al.
Publicado: (2023) -
IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Dai, Jia, et al.
Publicado: (2013)